Skip to content

Effect of Astocalm plus tablets in healthy volunteers

Comparative evaluation of Astocalm plus tablets along with Ashwagandha churna tablet (500 mg) and StressCom capsules of Dabur in reducing salivary alpha amylase, salivary cortisol and behavioural change in healthy volunteers - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/10/058179
Enrollment
40
Registered
2023-10-03
Start date
Unknown
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: Z733- Stress, not elsewhere classified

Interventions

Intervention1: Astocalm plus tablets: Taken orally once daily at night for 1 week Control Intervention1: StressCom capsules: Taken orally once daily at night for 1 week

Sponsors

Dr.JRK’s Research and Pharmaceuticals Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Healthy volunteers (age 25- 48 both genders) 2. People with diabetes mellitus 3. People who suffer from chronic pain 4. People who complain stress, anxiety and forgetfulness 5. Who are not taking any anxiolytic drugs or sedative anti-histamines 6. Willing to take the herbal drug 7. Willing to give saliva sample in the Eppendorf as per the instruction and time line

Exclusion criteria

Exclusion criteria: 1 People who are on anti-histaminic treatment 2. Who are on steroid or strong anti-inflammatory drugs 3. Unwilling to take herbal drugs

Design outcomes

Primary

MeasureTime frame
1.Salivary alpha amylase and salivary cortisol (Time points: Day 0 and day 3) 2.Questionnaire(Time points: Day 0 and day 3)Timepoint: Day 0 and Day 3

Secondary

MeasureTime frame
To evaluate Adverse events & serious adverse events during the study period Timepoint: Day 0 & Day 3

Countries

India

Contacts

Public ContactDr gayathri Shivakumar

KI3, CRO

mounicool02@gmail.com8056328566

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026